Literature DB >> 17013809

The evolution of progesterone receptor ligands.

Kevin P Madauss1, Eugene L Stewart, Shawn P Williams.   

Abstract

Progesterone is one of the first nuclear receptor hormones to be described functionally and subsequently approached as a drug target. Because progesterone (1) affects both menstruation and gestation via the progesterone receptor (PR), research aimed at modulating its activity is usually surrounded by controversy. However, ligands for PR were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of progesterone; (2) drug-like steroids with different properties from progesterone and expanded therapeutic applications; and (3) non-steroidal PR ligands with improved selectivity and modulator properties and further expanded therapeutic applications. Although the latter have yet to see widespread clinical applications, their development is founded on a half century of research, and they represent the future for this drug target. (c) 2006 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17013809     DOI: 10.1002/med.20083

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  14 in total

1.  Deciphering modern glucocorticoid cross-pharmacology using ancestral corticosteroid receptors.

Authors:  Jeffrey A Kohn; Kirti Deshpande; Eric A Ortlund
Journal:  J Biol Chem       Date:  2012-03-21       Impact factor: 5.157

2.  X-ray structures of progesterone receptor ligand binding domain in its agonist state reveal differing mechanisms for mixed profiles of 11β-substituted steroids.

Authors:  Scott J Lusher; Hans C A Raaijmakers; Diep Vu-Pham; Bert Kazemier; Rolien Bosch; Ross McGuire; Rita Azevedo; Hans Hamersma; Koen Dechering; Arthur Oubrie; Marcel van Duin; Jacob de Vlieg
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

Review 3.  Endometriosis and nuclear receptors.

Authors:  Bahar D Yilmaz; Serdar E Bulun
Journal:  Hum Reprod Update       Date:  2019-07-01       Impact factor: 15.610

4.  Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators.

Authors:  Scott J Lusher; Hans C A Raaijmakers; Diep Vu-Pham; Koen Dechering; Tsang Wai Lam; Angus R Brown; Niall M Hamilton; Olaf Nimz; Rolien Bosch; Ross McGuire; Arthur Oubrie; Jacob de Vlieg
Journal:  J Biol Chem       Date:  2011-08-17       Impact factor: 5.157

5.  A Selective Ligand for Estrogen Receptor Proteins Discriminates Rapid and Genomic Signaling.

Authors:  Chetana M Revankar; Cristian G Bologa; Richard A Pepermans; Geetanjali Sharma; Whitney K Petrie; Sara N Alcon; Angela S Field; Chinnasamy Ramesh; Matthew A Parker; Nikolay P Savchuk; Larry A Sklar; Helen J Hathaway; Jeffrey B Arterburn; Tudor I Oprea; Eric R Prossnitz
Journal:  Cell Chem Biol       Date:  2019-11-06       Impact factor: 8.116

6.  A new strategy for selective targeting of progesterone receptor with passive antagonists.

Authors:  Junaid A Khan; Abdellatif Tikad; Michel Fay; Abdallah Hamze; Jérôme Fagart; Nathalie Chabbert-Buffet; Geri Meduri; Larbi Amazit; Jean-Daniel Brion; Mouad Alami; Marc Lombès; Hugues Loosfelt; Marie-Edith Rafestin-Oblin
Journal:  Mol Endocrinol       Date:  2013-04-11

Review 7.  Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.

Authors:  Md Soriful Islam; Sadia Afrin; Sara Isabel Jones; James Segars
Journal:  Endocr Rev       Date:  2020-10-01       Impact factor: 19.871

8.  A PROSS-designed extensively mutated estrogen receptor α variant displays enhanced thermal stability while retaining native allosteric regulation and structure.

Authors:  Mark Kriegel; Hanna J Wiederanders; Sewar Alkhashrom; Jutta Eichler; Yves A Muller
Journal:  Sci Rep       Date:  2021-05-18       Impact factor: 4.379

9.  Oral contraceptive progestins and angiotensin-dependent control of the renal circulation in humans.

Authors:  M A Sarna; N K Hollenberg; E W Seely; S B Ahmed
Journal:  J Hum Hypertens       Date:  2009-01-22       Impact factor: 3.012

10.  Lack of in vitro effect of aglepristone on IFN-γ and IL-4 production by resting and mitogen-activated T cells of luteal bitches.

Authors:  Piotr Jurka; Lidia Szulc-Dąbrowska; Joanna Borkowska; Anna Winnicka
Journal:  BMC Vet Res       Date:  2013-10-26       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.